2D/3D EX vivo Assays: A PDX-based platform for ex vivo evaluating/screening novel anti-cancer compoundsIMODI Cancer

Oncomedics has developed the Oncogramme®, based on primary culture of cells from human tumor tissues. It creates a functional profile of a patient tumor’s sensitivity and resistance to various drugs/drug candidates and combinations to provide physicians with the most accurate information for treating a patient’s cancer. Functional assays are also useful at preclinical stages of drug candidates’ development. Oncomedics has thus developed OncoTRIP™ (Tumor Response Index & Profiling), a exclusive, centralized ex vivo platform for profiling of new agents on tumor-derived primary cultures.
We offer an array of testing services centered on cells from patient-derived tumor xenografts (PDXs). A unique collection of highly characterized PDX cancer models is integrated and available through Oncodesign’s X-Mice® platform. Specific tumor profiles can therefore be selected for phenotypic exploration (2D/3D models; spheroids) with OncoTRIP™, which is ideally designed and positioned for:

• profiling and qualification of drug candidates;
• selection of relevant tumor models for further in vivo testing.

OncoTRIP™ is an enabling tool bridging advances made in primary cell culture with hard-to-collect, -grow and -investigate patient-derived solid tumor cells. We assist biotechnology and pharmaceutical companies to improve drug candidate validation and reduce time to market.

2D primary culture from non-small cell lung cancer PDX in Oncomedics’ proprietary defined medium


2D primary culture from breast cancer PDX in Oncomedics’ proprietary defined medium, showing emergence of spheroids

---

Restez connectés !

IMODI est maintenant présent sur les réseaux sociaux.
Suivez-nous sur : @IMODI_Cancer et www.linkedin.com/company/imodi-cancer